Scarica l'app Stockscreener
12.44
6.33%
-0.84
Dopo l'orario di chiusura:
12.51
0.07
+0.56%
Precedente Chiudi:
$13.28
Aprire:
$12.95
Volume 24 ore:
4.69M
Relative Volume:
0.93
Capitalizzazione di mercato:
$1.74B
Reddito:
$67.67M
Utile/perdita netta:
$-412.69M
Rapporto P/E:
-3.2509
EPS:
-3.8266
Flusso di cassa netto:
$-395.87M
1 W Prestazione:
+5.16%
1M Prestazione:
+13.92%
6M Prestazione:
-1.58%
1 anno Prestazione:
+21.84%
Intervallo 1D:
$12.29
$13.04
Intervallo di 1 settimana:
$11.41
$13.35
Portata 52W:
$7.95
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Nome
Intellia Therapeutics Inc
Settore
Industria
Telefono
857-285-6200
Indirizzo
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
12.44 | 1.86B | 67.67M | -412.69M | -395.87M | -3.8266 |
VRTX
Vertex Pharmaceuticals Inc
|
540.26 | 139.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
826.64 | 86.57B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,038.12 | 64.62B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
133.32 | 69.62B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.74 | 46.01B | 742.00K | -1.37B | -1.07B | -7.0731 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-02 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2025-11-12 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-11-11 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-11-07 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-10-28 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2025-10-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-10-27 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-10-06 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-21 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2025-02-28 | Downgrade | Goldman | Neutral → Sell |
| 2025-02-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-04-13 | Iniziato | Canaccord Genuity | Buy |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-03-14 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-01-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-21 | Iniziato | JP Morgan | Overweight |
| 2022-09-01 | Iniziato | Citigroup | Sell |
| 2022-06-17 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-06-16 | Iniziato | BofA Securities | Buy |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-02-18 | Iniziato | William Blair | Outperform |
| 2022-02-07 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Iniziato | Cowen | Outperform |
| 2022-01-07 | Iniziato | Piper Sandler | Overweight |
| 2021-10-05 | Iniziato | Guggenheim | Buy |
| 2021-09-24 | Iniziato | Stifel | Buy |
| 2021-06-28 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-11 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-07 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Iniziato | Truist | Buy |
| 2020-10-14 | Iniziato | Wells Fargo | Overweight |
| 2020-09-18 | Iniziato | Goldman | Buy |
| 2020-02-28 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-11-01 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Iniziato | Robert W. Baird | Outperform |
| 2019-06-10 | Iniziato | ROTH Capital | Neutral |
| 2019-05-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-11-02 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-10-29 | Iniziato | Credit Suisse | Neutral |
| 2018-09-21 | Iniziato | Raymond James | Mkt Perform |
| 2018-05-15 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2017-11-01 | Reiterato | Jefferies | Buy |
| 2017-06-22 | Ripresa | Jefferies | Buy |
| 2017-03-28 | Iniziato | Chardan Capital Markets | Buy |
| 2016-08-05 | Aggiornamento | Jefferies | Hold → Buy |
Mostra tutto
Intellia Therapeutics Inc Borsa (NTLA) Ultime notizie
John M. Leonard to sell 22,675 Intellia (NASDAQ: NTLA) shares - Stock Titan
Intellia Therapeutics (NASDAQ:NTLA) Shares Down 6.4%Time to Sell? - MarketBeat
NTLA Stock Rockets After Hours Before Critical Data For Genetic Disorder Therapy - Stocktwits
Bank of America Corp DE Grows Stock Position in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Stock Price Up 10.7%Here's What Happened - MarketBeat
Will Narrowing Six‑Month Losses Shape Intellia Therapeutics' (NTLA) Gene‑Editing Investment Narrative? - Sahm
NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - Stocktwits
Why Is NTLA Stock Jumping 5% Premarket Today? - Stocktwits
NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late - Stocktwits
NTLA|Intellia Therapeutics Inc|Price:11.910|Chg%:+0.080 - TradingKey
JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $29 - Moomoo
Intellia (NTLA) Q2 2026 Earnings Call Transcript - The Globe and Mail
Wasatch Advisors LP Sells 134,215 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat
Intellia Therapeutics Stock Short Interest Falls to 39.57% - Quiver Quantitative
Intellia Therapeutics, Inc. $NTLA Shares Acquired by Royal Bank of Canada - MarketBeat
(NTLA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Research Analysts Offer Predictions for NTLA FY2026 Earnings - MarketBeat
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported And Analysts Have Been Cutting Their Estimates - webull.com
Intellia Therapeutics Insider Buyers See Boost After Market Cap Rose US$168m - Moomoo
Equities Analysts Issue Forecasts for NTLA Q2 Earnings - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Issues Earnings Results - MarketBeat
Bank of America Securities Remains a Hold on Intellia Therapeutics (NTLA) - The Globe and Mail
Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Lowered by Wall Street Zen - MarketBeat
NTLA SWOT Analysis: Financial Resilience Amidst Clinical Advancements Revealed in 10-Q Filing - GuruFocus
Intellia Therapeutics Inc earnings matched, revenue fell short of estimates By Investing.com - Investing.com Nigeria
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues - Yahoo Finance
State Street (NTLA) stake: 9.23M Intellia Therapeutics shares in 13G filing - Stock Titan
Intellia upgraded at Evercore ISI on nex-z hypothesis (NTLA:NASDAQ) - Seeking Alpha
Intellia Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit - Yahoo Finance
Intellia Therapeutics, Inc. (NTLA) Stock Analysis: Exploring Potential 127.65% Upside with CRISPR Innovations - DirectorsTalk Interviews
Will Intellia’s (NTLA) Narrowing Losses and Heavy R&D Spend Shift Its Risk Reward Narrative? - Yahoo Finance
Intellia Therapeutics Q2 Earnings Call Highlights - MarketBeat
Intellia Therapeutics Inc (NTLA) (Q2 2026) Earnings Call Highlights: Advancing LONVOSI Toward ... By GuruFocus - Investing.com Canada
Intellia Therapeutics, Inc. Stock 12‑Month Price Target Cut to $25.56, Implies 133% Upside - tradingview.com
Intellia Therapeutics 2Q 2026: Revenue $7.7M, Net loss $106.6M, EPS $(0.80) — 10-Q Summary - TradingView
[10-Q] Intellia Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Intellia Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Intellia Therapeutics Inc (NTLA) (Q2 2026) Earnings Call Highlig - GuruFocus
Intellia Therapeutics Inc (NTLA) (Q2 2026) Earnings Call Highlights: Advancing LONVOSI Toward ... - Yahoo Finance
Form 8K Intellia Therapeutics Inc For: 6 August By Investing.com - Investing.com South Africa
Earnings call transcript: Intellia posts Q2 2026 revenue miss as shares slip premarket - Investing.com
Wedbush Adjusts Intellia Therapeutics Price Target to $12 From $17, Maintains Neutral Rating - marketscreener.com
Intellia Therapeutics Inc earnings matched, revenue fell short of estimates - Investing.com
INTELLIA THERAPEUTICS, INC. reports results for the quarter ended June 30Earnings Summary - TradingView
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Intellia Therapeutics reports Q2 2026 net loss of $106.6M, $628.4M cash; positive Phase 3 data for lonvo-z - TradingView
Earnings Flash (NTLA) Intellia Therapeutics, Inc. Reports Q2 Revenue $7.7M, Vs. FactSet Est of $13.0M - Moomoo
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates - Intellia Therapeutics
Intellia Therapeutics Q2 Operating Expenses U - moomoo.com
Intellia Therapeutics Inc Azioni (NTLA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):